0      0

28th Annual North American Cystic Fibrosis Conference

S16: NT-CFTR: Treating Every Patient: Theratype Approaches to CF Intervention

Oct 11, 2014 10:30am ‐ Oct 11, 2014 12:20pm

Standard: $49.99


The session will focus on new therapeutic approaches for CF patients carrying non-F508 mutations. Mutations have traditionally been grouped by their according to type (nonsense, missense, etc.) or by the CFTR functional classes. However, in the era of novel therapies it may be more useful to characterize mutations in terms of their response to particular therapies. We will discuss the CFTR2 project and how it has defined the genetic epidemiology across North America and Europe. We will also introduce therapeutic approaches for patients carrying nonsense and splicing mutations as well as the option of clinical trials for patients carrying rare or private mutations.

Learning Objectives:
  • Summarize the distribution of CFTR mutations woldwide.
  • Describe how CFTR mutations can be characterized according to response to therapies
  • Assess novel therapies directed at non F508del CFTR mutations


You must be logged in and own this session in order to post comments.